Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Ovarian Neoplasms 3Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Estrogen Receptor and/or Progesterone Receptor Positive 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Calcinosis 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 26fludarabine 16Etoposide 15Melphalan 13romidepsin 12Gemcitabine 11Whole-Body Irradiation 10Vincristine 10Peripheral Blood Stem Cell Transplantation 10Doxorubicin 10fludarabine phosphate 9Rituximab 9Lenalidomide 9Cytarabine 9Busulfan 9pembrolizumab 8Prednisone 8Mycophenolic Acid 8Granulocyte Colony-Stimulating Factor 8Bortezomib 8Filgrastim 7Carmustine 7Brentuximab Vedotin 7Biopsy 7duvelisib 6Tacrolimus 6Specimen Handling 6Dexamethasone 6Bendamustine Hydrochloride 6ruxolitinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, T-Cell × Pharmacogenomic Variants × Clear all
NCT03259503 2025-11-10

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 1 Completed
50 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡